GlassScriptPhysician profile
Mohammad A Haque
NPI 1609848266
$3,496.51
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $736 · 2021: $1,503 · 2022: $395 · 2023: $18.00 · 2024: $17.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $538.93 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $482.51 | 2019-2022 | |
| Novo Nordisk INC | $371.26 | 2020-2022 | |
| Pfizer INC. | $295.81 | 2019-2022 | |
| Abbvie INC. | $202.29 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $193.96 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $179.88 | 2019-2021 | |
| Allergan, INC. | $149.79 | 2019-2020 | |
| Amarin Pharma, INC. | $123.71 | 2020-2021 | |
| Glaxosmithkline, LLC. | $101.24 | 2019-2021 | |
| Abbott Laboratories | $90.43 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $87.25 | 2019 | |
| Amgen INC. | $62.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $61.07 | 2019-2021 | |
| Lilly USA, LLC | $59.35 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $59.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.41 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $51.35 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $49.02 | 2021 | |
| Kci USA, INC. | $30.76 | 2022 | |
| Melinta Therapeutics, LLC | $28.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.46 | 2019-2020 | |
| Dexcom, INC. | $21.86 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.78 | 2020 | |
| Gilead Sciences, INC. | $19.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.18 | 2022 | |
| Exact Sciences Corporation | $17.31 | 2024 | Cologuard Collection Kit |
| Sk Life Science, INC. | $17.09 | 2020 | |
| Mylan Specialty L.P. | $16.76 | 2019 | |
| Convatec INC. | $16.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2022 | |
| Ethicon US, LLC | $16.03 | 2019 | |
| Vivus LLC | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.